The Pharmaceutical Innovation Index seeks to answer the provocative question, ‘If two pharma companies were given the same molecule in early phase, which of the two would be better in developing and launching it?”
The Innovation Index ranks companies utilizing a range of clinical, regulatory, and commercial metrics, ranging from the corporate level down to individual product decisions and outcomes.
This 12th annual Index provides a systematic and objective assessment of how well the top 30 companies perform in bringing new medicines to market and commercializing them successfully.
